Physician profile
Waina Cheng
NPI 1922283126
$6,941.24
in general payments reported to CMS, 2019-2025
53 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $790 · 2021: $895 · 2022: $1,196 · 2023: $971 · 2024: $973 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,977 · Education: $95.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,976.99 |
| Education | $95.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $848.49 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $708.05 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $628.49 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Novartis Pharmaceuticals Corporation | $603.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $456.97 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Amgen INC. | $289.40 | 2019-2023 | Vectibix, Nplate, Xgeva |
| Pfizer INC. | $275.97 | 2019-2025 | |
| Genentech USA, INC. | $255.54 | 2019-2025 | Tecentriq, Alecensa, Polivy |
| Daiichi Sankyo INC. | $231.60 | 2019-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $229.80 | 2019-2025 | |
| Incyte Corporation | $225.03 | 2019-2025 | Jakafi |
| Genzyme Corporation | $195.61 | 2019-2022 | |
| Celgene Corporation | $193.54 | 2020-2025 | Reblozyl, Opdualag |
| Lilly USA, LLC | $121.74 | 2019-2023 | Retevmo, Jaypirca, Verzenio |
| Ipsen Biopharmaceuticals, INC | $112.36 | 2019-2022 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $111.43 | 2019-2025 | Libtayo |
| Gilead Sciences, INC. | $104.24 | 2019-2023 | Trodelvy |
| Glaxosmithkline, LLC. | $99.23 | 2021-2024 | Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $94.42 | 2021-2025 | Ninlaro, Iclusig |
| Array Biopharma INC | $80.78 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Kite Pharma, INC. | $73.83 | 2020-2023 | |
| Rigel Pharmaceuticals, INC. | $60.53 | 2021-2024 | Rezlidhia, Tavalisse |
| Seagen INC. | $55.29 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $52.30 | 2023-2025 | Xpovio |
| Astellas Pharma US INC | $52.14 | 2022-2023 | Xtandi |
| Geron Corporation | $51.22 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $48.37 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $48.07 | 2020-2025 | Orserdu |
| Myriad Genetic Laboratories, INC. | $47.01 | 2022-2023 | Myrisk |
| Pharmaessentia USA Corporation | $44.16 | 2023-2024 | Besremi |
| Emd Serono, INC. | $41.92 | 2020-2024 | |
| Jazz Pharmaceuticals INC. | $35.63 | 2022-2023 | Zepzelca |
| Acrotech Biopharma INC. | $35.39 | 2025 | Beleodaq |
| Adaptive Biotechnologies Corporation | $35.30 | 2022-2023 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $32.20 | 2020-2025 | Ultomiris |
| Caris Mpi, INC. | $31.38 | 2025 | Mi Cancer Seek |
| Sumitomo Pharma America, INC. | $30.28 | 2023 | Orgovyx |
| Myovant Sciences INC. | $29.83 | 2022 | |
| Cti Biopharma Corp. | $28.88 | 2023 | Vonjo |
| Exelixis INC. | $27.27 | 2022-2024 | Cabometyx |
| Taiho Oncology, INC. | $23.31 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $22.63 | 2019-2020 | |
| Sobi, INC | $18.91 | 2024 | |
| Novo Nordisk INC | $17.45 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.53 | 2023 | Gilotrif |
| Morphosys, US INC. | $15.68 | 2022 | |
| Puma Biotechnology, INC. | $15.61 | 2023 | |
| Eisai INC. | $15.00 | 2021 | |
| Foundation Medicine, INC. | $14.99 | 2019 | |
| Immunogen, INC. | $14.95 | 2023 | Elahere |
| Pharmacyclics LLC, An Abbvie Company | $13.61 | 2019 | |
| Abbvie INC. | $13.60 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waina Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.